A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of Sildenafil in the Treatment of Patients With Pulmonary Hypertension Associated to Chronic Obstructive Lung Disease
Latest Information Update: 27 Feb 2017
Price :
$35 *
At a glance
- Drugs Sildenafil (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms SPHERIC-1
- 02 Nov 2013 New trial record
- 11 Sep 2013 Primary endpoint 'Pulmonary-vascular-resistance' has been met.
- 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.